Regentis Biomaterials Ltd. (NYSE American: RGNT) is making progress with GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists, according to a press release.
GelrinC® aims to offer an alternative to traditional microfracture and complex cell-based therapies. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The implant has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled.
Regentis is positioning itself for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission. The company's Gelrin platform technology, based on synchronized, degradable hydrogel implants, is designed to regenerate damaged or diseased tissue including inflamed cartilage and bone.
For more information, a full corporate profile is available at https://ibn.fm/bpPp6.
